Enter a player name to begin or load your saved progress.
Glaxo originated in London in the early 1900s, focusing initially on pharmaceutical research.
Answer: False
Explanation: Glaxo originated in New Zealand in 1873 as Joseph Nathan and Co., later becoming Glaxo Laboratories in London, with its initial significant product being a dried-milk baby food.
Glaxo Laboratories obtained a listing on the London Stock Exchange in 1935.
Answer: False
Explanation: Glaxo Laboratories was incorporated as a distinct subsidiary in London in 1935, but it obtained its listing on the London Stock Exchange in 1947.
Beecham Group was founded by Thomas Beecham in 1848, initially selling patent medicines.
Answer: True
Explanation: Thomas Beecham founded the Beecham Group in 1848, commencing operations with the sale of patent medicines, notably Beecham's Pills.
By the 1960s, Beecham was primarily focused on consumer products like toothpaste and beverages.
Answer: False
Explanation: While Beecham was involved in consumer products, by the 1960s, it was also extensively involved in pharmaceuticals and research into synthetic penicillin, not solely focused on consumer goods.
What was the initial product that gained significant recognition for the company that originated as Joseph Nathan and Co. (later Glaxo)?
Answer: A dried-milk baby food called "Glaxo"
Explanation: The company that originated as Joseph Nathan and Co. (later Glaxo) gained significant recognition for its initial product: a dried-milk baby food marketed as "Glaxo."
What was the initial product launched by Thomas Beecham in 1848?
Answer: Beecham's Pills laxative
Explanation: Thomas Beecham launched his initial product, Beecham's Pills laxative, in 1848.
GSK plc was established through the merger of Glaxo Wellcome and SmithKline Beecham in December 2000.
Answer: True
Explanation: The merger of Glaxo Wellcome and SmithKline Beecham in December 2000 created GlaxoSmithKline (GSK), establishing it as one of the world's largest pharmaceutical companies at that time.
The merger of Glaxo and Wellcome in 1995 created the company known today as GSK plc.
Answer: False
Explanation: The merger of Glaxo and Wellcome in 1995 created Glaxo Wellcome plc. The company known today as GSK plc was formed later, in 2000, through the merger of Glaxo Wellcome and SmithKline Beecham.
SmithKline Beckman merged with Beecham Group in 1989 to form SmithKline Beecham P.L.C., moving its headquarters to England.
Answer: True
Explanation: In 1989, SmithKline Beckman merged with Beecham Group, creating SmithKline Beecham P.L.C., and subsequently relocated its headquarters to England.
What was the primary corporate action that established GSK plc?
Answer: The merger of Glaxo Wellcome and SmithKline Beecham.
Explanation: GSK plc was established through the significant corporate action of merging Glaxo Wellcome and SmithKline Beecham in December 2000, creating one of the world's largest pharmaceutical companies.
Which merger in 1995 created Glaxo Wellcome plc?
Answer: Glaxo and Wellcome
Explanation: The merger between Glaxo and Wellcome in 1995 resulted in the formation of Glaxo Wellcome plc.
Which company did SmithKline Beckman merge with in 1989?
Answer: Beecham Group
Explanation: In 1989, SmithKline Beckman merged with Beecham Group to form SmithKline Beecham P.L.C.
GSK's legacy companies included amoxicillin and zidovudine on the World Health Organization's List of Essential Medicines.
Answer: True
Explanation: The legacy companies of GSK were responsible for developing several products, including amoxicillin and zidovudine, which are recognized on the World Health Organization's List of Essential Medicines.
By 1999, Glaxo Wellcome was a leading manufacturer of drugs for asthma and HIV/AIDS.
Answer: True
Explanation: By 1999, Glaxo Wellcome had established itself as the world's largest manufacturer of pharmaceuticals for both asthma and HIV/AIDS.
GSK acquired Stiefel Laboratories in 2009 for $3.6 billion, strengthening its dermatology business.
Answer: True
Explanation: GSK completed the acquisition of Stiefel Laboratories in 2009 for $3.6 billion, a strategic move that significantly enhanced its presence in the dermatology sector.
GSK divested its entire pharmaceutical business to Novartis in 2014 as part of an asset swap.
Answer: False
Explanation: In 2014, GSK divested its cancer business to Novartis as part of an asset swap, not its entire pharmaceutical business.
The split of GSK's consumer healthcare division resulted in the creation of a new company named GSK Health.
Answer: False
Explanation: The split of GSK's consumer healthcare division resulted in the creation of a new, independent company named Haleon, not GSK Health.
GSK acquired Affinivax in May 2022 to bolster its vaccine development pipeline.
Answer: True
Explanation: GSK acquired Affinivax in May 2022, a strategic move aimed at strengthening its vaccine development pipeline.
GSK primarily manufactures products for respiratory diseases and oncology.
Answer: False
Explanation: While GSK is involved in respiratory diseases and oncology, its primary manufacturing focus also includes areas such as infections, diabetes mellitus, and mental health.
GSK's consumer healthcare division includes brands like Sensodyne toothpaste and previously owned Lucozade.
Answer: True
Explanation: GSK's consumer healthcare division encompasses brands such as Sensodyne toothpaste, and it formerly owned popular beverage brands like Lucozade and Ribena.
By 1999, in which two therapeutic areas was Glaxo Wellcome considered the world's largest manufacturer?
Answer: Asthma and HIV/AIDS
Explanation: By 1999, Glaxo Wellcome held the position of the world's largest manufacturer for drugs targeting asthma and HIV/AIDS.
What significant acquisition did GSK complete in 2009, related to dermatology?
Answer: Stiefel Laboratories
Explanation: In 2009, GSK acquired Stiefel Laboratories, a prominent independent dermatology company, thereby strengthening its position in that market.
In which year did GSK divest its beverage division, including Lucozade and Ribena?
Answer: 2013
Explanation: GSK divested its beverage division, which included Lucozade and Ribena, in 2013.
What is the name of the company formed from GSK's consumer healthcare division split?
Answer: Haleon
Explanation: The company formed from the split of GSK's consumer healthcare division is named Haleon.
GSK acquired Sierra Oncology Inc. in April 2022 for approximately how much?
Answer: $1.9 billion
Explanation: GSK acquired Sierra Oncology Inc. in April 2022 for approximately $1.9 billion.
Which of the following is NOT listed as a major disease area for which GSK manufactures products?
Answer: Respiratory Illnesses
Explanation: GSK manufactures products for major disease areas including cancer, diabetes mellitus, and mental health. While respiratory illnesses are a focus, the question implies it's not listed as a *primary* area in the same context as the others provided in the options based on the source's emphasis.
What was the value of the acquisition of Tesaro by GSK in December 2018?
Answer: $5.1 billion
Explanation: GSK acquired Tesaro in December 2018 for a value of $5.1 billion, gaining control of the ovarian cancer treatment Zejula.
Which company acquired GSK's interest in its Indian unit, GlaxoSmithKline Consumer Healthcare Ltd, in December 2018?
Answer: Unilever
Explanation: Unilever acquired GSK's stake in its Indian consumer healthcare unit, GlaxoSmithKline Consumer Healthcare Ltd, in December 2018.
What was the value of the acquisition of Bellus Health Inc. by GSK in April 2023?
Answer: $2 billion
Explanation: GSK acquired Bellus Health Inc. in April 2023 for $2 billion.
GSK's acquisition of Aiolos Bio in February 2024 was intended to strengthen which area of its business?
Answer: Asthma
Explanation: The acquisition of Aiolos Bio in February 2024 was aimed at strengthening GSK's business in the area of asthma treatments.
What action did GSK take regarding its shareholding in Haleon in May 2024?
Answer: Sold off a 4.2% stake.
Explanation: In May 2024, GSK sold a 4.2% stake in Haleon, reducing its shareholding in the consumer healthcare business.
In 2012, GSK paid $3 billion to resolve allegations of healthcare fraud, including issues related to the marketing of Avandia and Paxil.
Answer: True
Explanation: GSK resolved allegations of healthcare fraud in 2012 by paying $3 billion, addressing issues concerning the marketing practices for drugs such as Avandia and Paxil, among others.
GSK has consistently ranked poorly in the Access to Medicines Index since its inception.
Answer: False
Explanation: GSK has consistently ranked highly in the Access to Medicines Index since its inception, demonstrating a commitment to improving access to essential medicines.
In 2013, GSK joined the AllTrials campaign, pledging to report only positive clinical trial results.
Answer: False
Explanation: In 2013, GSK joined the AllTrials campaign, pledging to report all clinical trial results, both positive and negative, not just positive ones.
The 1973 antitrust case against Glaxo Group Ltd. involved allegations of price-fixing for the antifungal drug griseofulvin.
Answer: True
Explanation: The 1973 antitrust case against Glaxo Group Ltd. and ICI centered on allegations of price-fixing and a patent pool related to the antifungal drug griseofulvin.
GSK was fined in New Zealand for misrepresenting the vitamin C content of Ribena.
Answer: True
Explanation: GSK faced a fine in New Zealand due to misrepresentations concerning the vitamin C content of its product, Ribena.
What was a key reason for GSK's $3 billion settlement with the US Department of Justice in 2012?
Answer: Promoting antidepressants Paxil and Wellbutrin for unapproved uses in adolescents.
Explanation: A primary reason for GSK's $3 billion settlement in 2012 was the promotion of its antidepressants, Paxil and Wellbutrin, for unapproved uses in adolescents.
What was the core issue in the 1973 antitrust case *United States v. Glaxo Group Ltd.*?
Answer: A patent pool and bulk-sale restriction on griseofulvin.
Explanation: The core issue in the 1973 antitrust case *United States v. Glaxo Group Ltd.* involved a patent pool and bulk-sale restriction concerning the antifungal drug griseofulvin.
GSK faced criticism for continuing operations in which country following its 2022 invasion of Ukraine?
Answer: Russia
Explanation: GSK faced criticism for continuing its operations in Russia after the country's 2022 invasion of Ukraine.
What was the outcome of the concerns raised about Ribena's vitamin C content in New Zealand?
Answer: GSK was fined for misrepresenting its vitamin C content.
Explanation: Concerns raised about Ribena's vitamin C content in New Zealand led to GSK being fined for misrepresenting the product's nutritional information.
The Pandemrix influenza vaccine, used during the 2009 H1N1 pandemic, was linked to an increased risk of what condition?
Answer: Narcolepsy
Explanation: The Pandemrix influenza vaccine, administered during the 2009 H1N1 pandemic, was associated with an increased risk of narcolepsy, particularly in younger populations.
What practice led to GSK being fined £37 million in the UK related to the drug paroxetine?
Answer: Paying generic companies to delay market entry.
Explanation: GSK was fined £37 million in the UK for engaging in the practice of paying generic drug companies to delay the market entry of their products, thereby maintaining higher prices for paroxetine.
In November 2023, GSK filed a lawsuit against which company regarding mRNA technology patents?
Answer: Moderna
Explanation: In November 2023, GSK initiated a lawsuit against Moderna, alleging violations of GSK's patents related to messenger RNA (mRNA) technology.
What did GSK commit to regarding clinical trial data starting in 2013?
Answer: To make past trial reports available and report future ones within a year.
Explanation: Starting in 2013, GSK committed to making its past clinical trial reports accessible and to reporting future trial results within one year of their conclusion.
GSK's 2012 settlement with the US DOJ included allegations related to which drug's safety data reporting?
Answer: Avandia
Explanation: The 2012 settlement between GSK and the US DOJ included allegations concerning the reporting of safety data for the drug Avandia.
GSK plc is headquartered in New York City, USA.
Answer: False
Explanation: GSK plc is headquartered in London, England, UK, not New York City.
GSK developed RTS,S, the world's first approved malaria vaccine.
Answer: True
Explanation: GSK successfully developed RTS,S, which holds the distinction of being the world's first approved malaria vaccine.
GSK committed in 2014 to make its malaria vaccine, RTS,S, available at a price significantly above its production cost.
Answer: False
Explanation: In 2014, GSK committed to making its malaria vaccine, RTS,S, available at a price that was five percent above its cost of production, not significantly above.
Gertrude B. Elion and George H. Hitchings, Nobel Prize winners, worked for Glaxo Wellcome.
Answer: False
Explanation: Gertrude B. Elion and George H. Hitchings were Nobel Prize winners who worked for Burroughs Wellcome, a predecessor company, not Glaxo Wellcome directly.
Emma Walmsley became the CEO of GSK in March 2017, marking the first time a woman held the CEO position.
Answer: True
Explanation: Emma Walmsley assumed the role of CEO of GSK in March 2017, achieving the distinction of being the company's first female chief executive.
The application for regulatory approval of RTS,S in 2014 was significant because it aimed to introduce the first vaccine against tuberculosis.
Answer: False
Explanation: The 2014 application for RTS,S was significant as it aimed to introduce the first vaccine against malaria, not tuberculosis.
GSK partnered with Sanofi to develop a COVID-19 vaccine using recombinant protein-based technology.
Answer: True
Explanation: GSK collaborated with Sanofi in the development of a COVID-19 vaccine, utilizing a combination of recombinant protein-based technology and GSK's pandemic adjuvant technology.
GSK operates SR One, established in 1985, solely for internal research and development funding.
Answer: False
Explanation: SR One, established by GSK (formerly SmithKline Beecham) in 1985, functions as a venture capital arm that invests in and out-licenses new biotechnology companies and drug candidates, not solely for internal funding.
Four GSK scientists have been recognized with Nobel Prizes for their contributions to medical science.
Answer: True
Explanation: Four scientists affiliated with GSK have received Nobel Prizes, acknowledging their significant contributions to basic medical science and the development of therapeutics.
Gertrude B. Elion and George H. Hitchings received the Nobel Prize for their work on synthetic penicillin.
Answer: False
Explanation: Gertrude B. Elion and George H. Hitchings received the Nobel Prize for their discoveries of important principles for drug treatment, including drugs for leukemia and gout, not synthetic penicillin.
Where is GSK plc currently headquartered?
Answer: London, England, UK
Explanation: GSK plc maintains its headquarters in London, England, UK.
Who were the Nobel Prize-winning scientists associated with Burroughs Wellcome known for discovering principles for drug treatment?
Answer: Gertrude B. Elion and George H. Hitchings
Explanation: Gertrude B. Elion and George H. Hitchings, associated with Burroughs Wellcome, were Nobel Prize winners recognized for discovering key principles in drug treatment.
Who became the CEO of GSK in March 2017?
Answer: Emma Walmsley
Explanation: Emma Walmsley assumed the position of CEO of GSK in March 2017.
GSK's venture capital arm, SR One, was established in what year?
Answer: 1985
Explanation: SR One, GSK's venture capital arm, was established in 1985.
What was the primary focus of the joint venture ViiV Healthcare, formed by GSK and Pfizer in 2009?
Answer: HIV research
Explanation: The joint venture ViiV Healthcare, established by GSK and Pfizer in 2009, primarily focuses on HIV research and treatment.